GILD241213C87000
- 5.90
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
Weekly Buzz: Tech stocks hit high scores on ominous day
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Market Mixed on Friday the 13th | Livestock
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences (GILD) Gets a Hold From Truist Financial
Gilead Gets Key European Backing for Liver-Disease Treatment
Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...
Express News | Gilead: Final European Commission Decision Is Anticipated in Q1 of 2025
Express News | Gilead’s Seladelpar Receives Positive Chmp Opinion for Primary Biliary Cholangitis
Gilead Sciences: Berger to Succeed Merdad Parsey on Jan. 2
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Express News | Gilead Sciences Appoints Dietmar Berger, Md, Phd, as Chief Medical Officer
Gilead Sciences Options Spot-On: On December 12th, 87,424 Contracts Were Traded, With 259.6K Open Interest
Thursday Ends in Index Declines | Wall Street Today
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Is Gilead Sciences (GILD) Stock Undervalued Right Now?
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105